BCH


CAS No. : 20448-79-7

(Synonyms: 2-Amino-2-norbornanecarboxylic acid; LAT1-IN-1)

20448-79-7
Price and Availability of CAS No. : 20448-79-7
Size Price Stock
50mg $66 In-stock
100mg $110 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-108540
M.Wt: 155.20
Formula: C8H13NO2
Purity: >98 %
Solubility: H2O : 20 mg/mL (ultrasonic;warming;heat to 60°C);DMSO : < 1 mg/mL
Introduction of 20448-79-7 :

BCH (2-Amino-2-norbornanecarboxylic acid) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis[1][2][3]. IC50 & Target:LAT1[1] In Vitro:BCH (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner[1].
BCH (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that BCH induces cell cycle arrest at G1 phase[1].
BCH (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased[1]. In Vivo:BCH (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo[1].

Your information is safe with us.